Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926016 · ClinicalTrials.gov registry record · NA
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
A NA study, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT00926016 is a NA study that has completed, run by Brooke Army Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT00926016, a NA study, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
Interventions
- DRUG Pioglitazone (Actos)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00926016
The ClinicalTrials.gov registry entry for NCT00926016 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brooke Army Medical Center, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pioglitazone (Actos) is the first listed.
NCT00926016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00926016 about?
NCT00926016 is a clinical study titled "Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects". The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
What is the current status of trial NCT00926016?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2006-06. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00926016?
The interventions under investigation include: Pioglitazone (Actos) (DRUG).
Who is sponsoring clinical trial NCT00926016?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.